Your browser doesn't support javascript.
loading
Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment.
Boeri, Marco; Sutphin, Jessie; Hauber, Brett; Cappelleri, Joseph C; Romero, William; Di Bonaventura, Marco.
Afiliación
  • Boeri M; RTI Health Solutions, Belfast, UK.
  • Sutphin J; RTI Health Solutions, Research Triangle Park, NC, USA.
  • Hauber B; RTI Health Solutions, Research Triangle Park, NC, USA.
  • Cappelleri JC; Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington School of Pharmacy, Seattle, WA, USA.
  • Romero W; Pfizer Inc, Groton, CT, USA.
  • Di Bonaventura M; Pfizer Ltd, Surrey, UK.
J Dermatolog Treat ; 33(3): 1449-1458, 2022 May.
Article en En | MEDLINE | ID: mdl-33023361
ABSTRACT

OBJECTIVES:

To identify meaningful treatment attributes and quantify patient preferences for attributes of systemic atopic dermatitis (AD) treatments. MATERIALS AND

METHODS:

Qualitative interviews were conducted with adults with moderate-to-severe AD (N = 21) to identify AD treatment attributes that patients consider most important and inform attribute selection for an online discrete-choice experiment (DCE) survey administered to patients in the United States with moderate-to-severe AD. Participants identified probability of clear/almost clear skin at 16 weeks, time to itch relief, mode of administration, and safety risks as very important. DCE data were analyzed using a random-parameters logit model to estimate the relative importance of treatment attributes and maximum acceptable risk.

RESULTS:

A total of 320 respondents completed the DCE survey (74% female; mean age, 35 years). Annual risk of malignancy was the most important attribute, followed by mode of administration, probability of clear skin at 16 weeks, and time to onset of itch relief. Respondents preferred daily oral treatment over injectable treatment. Respondents were willing to accept increases in adverse event risks for improvements in efficacy and mode of administration.

CONCLUSION:

The findings of this study can help inform joint patient-physician decision making in managing moderate-to-severe AD.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Dermatitis Atópica / Prioridad del Paciente Tipo de estudio: Prognostic_studies / Qualitative_research / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: J Dermatolog Treat Asunto de la revista: DERMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Dermatitis Atópica / Prioridad del Paciente Tipo de estudio: Prognostic_studies / Qualitative_research / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: J Dermatolog Treat Asunto de la revista: DERMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido